Protocol No. A0021002: A Phase III, Multicenter, Open-label, Dose Titrating, 16 Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20 Mg And 40 Mg Alone Or In Combination With 12.5 To 25 Mg Of Hydrochlorothiazide In Subjects With Mild To Moderate Essential Hypertension.
Link to ClinicalTrials.gov registration: http://www.clinicaltrials.gov/ct/show/NCT00139698?order=1
Pfizer will use reasonable efforts to include accurate and up-to-date information on the ClinicalStudyResults.org web site. However, because the status of studies often changes, Pfizer can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. You agree that access to and use of information posted by Pfizer on the ClinicalStudyResults.org web site is at your own risk. Pfizer disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Pfizer shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Pfizer on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof. The ClinicalStudyResults.org web site is maintained by PhRMA, a trade association of which Pfizer is a member. PhRMA had no role in the sponsorship or conduct of the studies posted by Pfizer on ClinicalStudyResults.org. |
